Preclinical biotech Hillstream BioPharma is working on groundbreaking new therapies aimed at combating drug-resistant cancers, according to company officials. Hillstream's research focuses on ferroptosis, an anti-cancer mechanism that triggers iron-mediated cell death, as well as developing targeted immuno-oncology biologics. The company's lead product candidate is HSB-1216, an inducer of iron-mediated cell death designed to work against solid tumors. Hillstream is also developing HSB-3215, an anti-HER2 monoclonal antibody, and HSB-1940, a Quatrabody IO biologic that targets PD-1. Founded in 2017, Hillstream is headquartered in Bridgewater, New Jersey.